# BioInvent Reports Positive Phase 1 Data for Cancer Drug BI-1808

- URL: https://stocks.freetheai.org/news/bioinvent-reports-positive-phase-1-data-for-cancer-drug-bi-1808-9582a6
- Published: 2026-10-15T14:00:00Z
- Category: company_news; sentiment: bullish; impact: medium
- Symbols: [OMXSTO:BINV](https://stocks.freetheai.org/symbols/OMXSTO-BINV)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

BioInvent International AB (OMXSTO:BINV) reported Phase 1 monotherapy trial results for its cancer drug candidate BI-1808. The study showed evidence of single-agent anti-tumor activity with CD8+ T cell infiltration, alongside an excellent safety profile.

The clinical data provides early validation for targeting TNFR2 in patients, helping de-risk dosing and development strategies. Demonstrating efficacy as a standalone treatment expands potential use cases for the asset and strengthens platform credibility.

Development moves forward in an ongoing Phase 1/2a trial. Investors and researchers will monitor confirmation of response rates and treatment durability, as well as results from cohorts evaluating BI-1808 in combination with pembrolizumab.

## Key points

- BioInvent reported Phase 1 monotherapy results showing anti-tumor activity for BI-1808.
- The treatment demonstrated an excellent safety profile and CD8+ T cell infiltration in patients.
- Clinical findings validate TNFR2 targeting and help de-risk the candidate's development.
- BI-1808 is currently in a Phase 1/2a trial, including combination testing with pembrolizumab.

## Questions and answers

### What did BioInvent report regarding BI-1808?

BioInvent reported Phase 1 monotherapy data demonstrating single-agent anti-tumor activity, CD8+ T cell infiltration, and an excellent safety profile for BI-1808.

### What is the current status of BI-1808 development?

BI-1808 is undergoing further evaluation in an active Phase 1/2a clinical trial, which includes testing in combination with pembrolizumab.